## Xavier de la Torre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1455223/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Electrospray mass spectrometry of testosterone esters: Potential for use in doping control. Steroids, 1997, 62, 523-529.	0.8	131
2	A screening method for the simultaneous detection of glucocorticoids, diuretics, stimulants, anti-oestrogens, beta-adrenergic drugs and anabolic steroids in human urine by LC-ESI-MS/MS. Analytical and Bioanalytical Chemistry, 2008, 392, 681-698.	1.9	106
3	The abuse of diuretics as performanceâ€enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis. British Journal of Pharmacology, 2010, 161, 1-16.	2.7	104
4	Toxicological determination and <i>in vitro</i> metabolism of the designer drug methylenedioxypyrovalerone (MPDV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole timeâ€ofâ€flight mass spectrometry. Rapid Communications in Mass Spectrometry, 2010, 24, 2706-2714.	0.7	98
5	13C/12C Isotope ratio MS analysis of testosterone, in chemicals and pharmaceutical preparations. Journal of Pharmaceutical and Biomedical Analysis, 2001, 24, 645-650.	1.4	83
6	Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans. Archives of Toxicology, 2019, 93, 1807-1816.	1.9	75
7	Fast screening of anabolic steroids and other banned doping substances in human urine by gas chromatography/tandem mass spectrometry. Journal of Mass Spectrometry, 2002, 37, 1059-1073.	0.7	71
8	Discrimination of Prohibited Oral Use of Salbutamol from Authorized Inhaled Asthma Treatment. Clinical Chemistry, 2000, 46, 1365-1375.	1.5	65
9	Changes in Androgenic Steroid Profile Due to Urine Contamination by Microorganisms: A Prospective Study in the Context of Doping Control. Analytical Biochemistry, 2001, 289, 116-123.	1.1	58
10	Hair analysis and detectability of single dose administration of androgenic steroid esters. Forensic Science International, 2000, 107, 347-359.	1.3	57
11	Analytical methodology for enantiomers of salbutamol in human urine for application in doping control. Biomedical Applications, 1999, 723, 173-184.	1.7	53
12	A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine. Rapid Communications in Mass Spectrometry, 2010, 24, 1697-1706.	0.7	50
13	Plasma and urinary markers of oral testosterone undecanoate misuse. Steroids, 2002, 67, 39-50.	0.8	47
14	Urine stability and steroid profile: Towards a screening index of urine sample degradation for anti-doping purpose. Analytica Chimica Acta, 2011, 683, 221-226.	2.6	44
15	Screening and confirmation analysis of stimulants, narcotics and beta-adrenergic agents in human urine by hydrophilic interaction liquid chromatography coupled to mass spectrometry. Journal of Chromatography A, 2011, 1218, 8156-8167.	1.8	42
16	Fast GC-MS method for the simultaneous screening of THC-COOH, cocaine, opiates and analogues including buprenorphine and fentanyl, and their metabolites in urine. Analytical and Bioanalytical Chemistry, 2011, 399, 1623-1630.	1.9	42
17	A Mass Spectrometric Approach for the Study of the Metabolism of Clomiphene, Tamoxifen and Toremifene by Liquid Chromatography Time-of-Flight Spectroscopy. European Journal of Mass Spectrometry, 2008, 14, 171-180.	0.5	40
18	A comprehensive procedure based on gas chromatography–isotope ratio mass spectrometry following high performance liquid chromatography purification for the analysis of underivatized testosterone and its analogues in human urine. Analytica Chimica Acta. 2012. 756. 23-29.	2.6	38

#	Article	IF	CITATIONS
19	Non-targeted LC-MS based metabolomics analysis of the urinary steroidal profile. Analytica Chimica Acta, 2017, 964, 112-122.	2.6	38
20	Oral Testosterone Administration Detected by Testosterone Glucuronidation Measured in Blood Spots Dried on Filter Paper. Clinical Chemistry, 2000, 46, 515-522.	1.5	37
21	A liquid chromatography–mass spectrometry method based on class characteristic fragmentation pathways to detect the class of indole-derivative synthetic cannabinoids in biological samples. Analytica Chimica Acta, 2014, 837, 70-82.	2.6	36
22	Detection of testosterone esters in human plasma. Journal of Mass Spectrometry, 1995, 30, 1393-1404.	0.7	35
23	SFC-MS/MS as an orthogonal technique for improved screening of polar analytes in anti-doping control. Analytical and Bioanalytical Chemistry, 2016, 408, 6789-6797.	1.9	34
24	Urinary Testosterone (T) To Epitestosterone (E) Ratios by GC/MS. I. Initial Comparison of Uncorrected T/E in Six International Laboratories. Journal of Mass Spectrometry, 1996, 31, 397-402.	0.7	31
25	Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies. Analytical and Bioanalytical Chemistry, 2013, 405, 5467-5487.	1.9	31
26	Development and validation of a liquid chromatography–mass spectrometry procedure after solid-phase extraction for detection of 19 doping peptides in human urine. Forensic Toxicology, 2015, 33, 321-337.	1.4	31
27	Targeting the administration of ecdysterone in doping control samples. Forensic Toxicology, 2020, 38, 172-184.	1.4	31
28	Determination of $\hat{I}^22$ -agonists in hair by gas chromatography/mass spectrometry. , 1996, 31, 47-54.		29
29	Relevance of the selective oestrogen receptor modulators tamoxifen, toremifene and clomiphene in doping field: Endogenous steroids urinary profile after multiple oral doses. Steroids, 2011, 76, 1400-1406.	0.8	28
30	A simplified procedure for GC/C/IRMS analysis of underivatized 19-norandrosterone in urine following HPLC purification. Steroids, 2011, 76, 471-477.	0.8	27
31	Liquid chromatography clean-up method to improve identification of anabolic agents in human urine by gas chromatography–mass spectrometry. Analytica Chimica Acta, 2004, 522, 79-88.	2.6	25
32	Drugâ€drug interaction and doping, part 2: An <i>in vitro</i> study on the effect of nonâ€prohibited drugs on the phase I metabolic profile of stanozolol. Drug Testing and Analysis, 2014, 6, 969-977.	1.6	23
33	A multi-targeted liquid chromatography–mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes. Journal of Pharmaceutical and Biomedical Analysis, 2016, 117, 47-60.	1.4	22
34	Rapid screening of betaâ€adrenergic agents and related compounds in human urine for antiâ€doping purpose using capillary electrophoresis with dynamic coating. Journal of Separation Science, 2009, 32, 3562-3570.	1.3	21
35	Narrowing the gap between the number of athletes who dope and the number of athletes who are caught: scientific advances that increase the efficacy of antidoping tests. British Journal of Sports Medicine, 2014, 48, 833-836.	3.1	21
36	Improving the detection of anabolic steroid esters in human serum by LC–MS. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113807.	1.4	21

#	Article	IF	CITATIONS
37	The Relevance of the Urinary Concentration of Ephedrines in Anti-Doping Analysis: Determination of Pseudoephedrine, Cathine, and Ephedrine After Administration of Over-the-Counter Medicaments. Therapeutic Drug Monitoring, 2009, 31, 520-526.	1.0	20
38	A rapid screening LCâ€MS/MS method based on conventional HPLC pumps for the analysis of low molecular weight xenobiotics: application to doping control analysis. Drug Testing and Analysis, 2010, 2, 311-322.	1.6	20
39	Combined chemical and biotechnological production of 20βOH-NorDHCMT, a long-term metabolite of Oral-Turinabol (DHCMT). Journal of Inorganic Biochemistry, 2018, 183, 165-171.	1.5	20
40	Mass spectrometric characterization of tamoxifene metabolites in human urine utilizing different scan parameters on liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2010, 24, 749-760.	0.7	19
41	Strategies for internal quality control in antidoping analyses. Analytica Chimica Acta, 2002, 460, 289-307.	2.6	18
42	Effects of propyphenazone and other non-steroidal anti-inflammatory agents on the synthetic and endogenous androgenic anabolic steroids urinary excretion and/or instrumental detection. Analytica Chimica Acta, 2010, 657, 60-68.	2.6	18
43	Improved ultrasonic-based sample treatment for the screening of anabolic steroids by gas chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 2010, 24, 2375-2385.	0.7	18
44	Analysis of Stimulants in Oral Fluid and Urine by Gas Chromatography-Mass Spectrometry II: Pseudophedrine. Journal of Analytical Toxicology, 2010, 34, 210-215.	1.7	17
45	Development and validation of a GCâ€Câ€IRMS method for the confirmation analysis of pseudoâ€endogenous glucocorticoids in doping control. Drug Testing and Analysis, 2015, 7, 1071-1078.	1.6	17
46	Effects of transdermal administration of testosterone gel on the urinary steroid profile in hypogonadal men: Implications in antidoping analysis. Steroids, 2019, 152, 108491.	0.8	17
47	Laboratory medicine and sports: between Scylla and Charybdis. Clinical Chemistry and Laboratory Medicine, 2012, 50, 1309-16.	1.4	16
48	Characterization of the phase I and phase II metabolic profile of tolvaptan by in vitro studies and liquid chromatography–mass spectrometry profiling: Relevance to doping control analysis. Journal of Pharmaceutical and Biomedical Analysis, 2017, 145, 555-568.	1.4	16
49	Development and application of analytical procedures for the GC–MS/MS analysis of the sulfates metabolites of anabolic androgenic steroids: The pivotal role of chemical hydrolysis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1155, 122280.	1.2	16
50	Drug Use on Mont Blanc: A Study Using Automated Urine Collection. PLoS ONE, 2016, 11, e0156786.	1.1	16
51	A fast gas chromatography/mass spectrometry method for the determination of stimulants and narcotics in urine. Rapid Communications in Mass Spectrometry, 2010, 24, 1475-1480.	0.7	15
52	Reference ranges for the urinary steroid profile in a Latinâ€American population. Drug Testing and Analysis, 2013, 5, 619-626.	1.6	15
53	A simplified procedure for the analysis of formoterol in human urine by liquid chromatography–electrospray tandem mass spectrometry: Application to the characterization of the metabolic profile and stability of formoterol in urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2013. 931. 75-83.	1.2	15
54	A further insight into the metabolic profile of the nuclear receptor Revâ€erb agonist, SR9009. Drug Testing and Analysis, 2018, 10, 1670-1681.	1.6	15

#	Article	IF	CITATIONS
55	Simultaneous detection of different chemical classes of selective androgen receptor modulators in urine by liquid chromatography-mass spectrometry-based techniques. Journal of Pharmaceutical and Biomedical Analysis, 2021, 195, 113849.	1.4	15
56	Detecting Autologous Blood Transfusion in Doping Control: Biomarkers of Blood Aging and Storage Measured by Flow Cytofluorimetry. Current Pharmaceutical Biotechnology, 2018, 19, 124-135.	0.9	15
57	Speeding up the process urine sample pre-treatment: Some perspectives on the use of microwave assisted extraction in the anti-doping field. Talanta, 2010, 81, 1264-1272.	2.9	14
58	Detection of new exemestane metabolites by liquid chromatography interfaced to electrospray-tandem mass spectrometry. Journal of Steroid Biochemistry and Molecular Biology, 2011, 127, 248-254.	1.2	14
59	Accelerated sample treatment for screening of banned doping substances by GC–MS: ultrasonication versus microwave energy. Analytical and Bioanalytical Chemistry, 2011, 399, 861-875.	1.9	14
60	Detection of formestane abuse by mass spectrometric techniques. Drug Testing and Analysis, 2014, 6, 1133-1140.	1.6	14
61	Urinary excretion profile of prednisone and prednisolone after different administration routes. Drug Testing and Analysis, 2019, 11, 1601-1614.	1.6	14
62	Fine-mapping of the substrate specificity of human steroid 21-hydroxylase (CYP21A2). Journal of Steroid Biochemistry and Molecular Biology, 2019, 194, 105446.	1.2	14
63	UPLC–MS-Based Procedures to Detect Prolyl-Hydroxylase Inhibitors of HIF in Urine. Journal of Analytical Toxicology, 2021, 45, 184-194.	1.7	14
64	Drug-drug interactions and masking effects in sport doping: influence of miconazole administration on the urinary concentrations of endogenous anabolic steroids. Forensic Toxicology, 2016, 34, 386-397.	1.4	13
65	New Insights into the Metabolism of Methyltestosterone and Metandienone: Detection of Novel A-Ring Reduced Metabolites. Molecules, 2021, 26, 1354.	1.7	13
66	Detection of new urinary exemestane metabolites by gas chromatography coupled to mass spectrometry. Steroids, 2011, 76, 1010-1015.	0.8	12
67	Isotope ratio mass spectrometry in antidoping analysis: The use of endogenous reference compounds. Rapid Communications in Mass Spectrometry, 2019, 33, 579-586.	0.7	12
68	How reliable is dietary supplement labelling?—Experiences from the analysis of ecdysterone supplements. Journal of Pharmaceutical and Biomedical Analysis, 2020, 177, 112877.	1.4	12
69	A further insight into methyltestosterone metabolism: New evidences from <i>in vitro</i> and <i>in vivo</i> experiments. Rapid Communications in Mass Spectrometry, 2020, 34, e8870.	0.7	12
70	<i>In vitro</i> evaluation of the effects of antiâ€fungals, benzodiazepines and nonâ€steroidal antiâ€inflammatory drugs on the glucuronidation of 19â€norandrosterone: implications on doping control analysis. Drug Testing and Analysis, 2016, 8, 930-939.	1.6	11
71	Longitudinal evaluation of the isotope ratio mass spectrometric data: towards the â€~isotopic module' of the athlete biological passport?. Drug Testing and Analysis, 2016, 8, 1212-1221.	1.6	11
72	Detection of urinary metabolites of arimistane in humans by gas chromatography coupled to highâ€accuracy mass spectrometry for antidoping analyses. Rapid Communications in Mass Spectrometry, 2019, 33, 1894-1905.	0.7	11

#	Article	IF	CITATIONS
73	7â€ketoâ€DHEAmetabolism in humans. Pitfalls in interpreting the analytical results in the antidoping field. Drug Testing and Analysis, 2019, 11, 1629-1643.	1.6	11
74	Analysis of exemestane and 17β-hydroxyexemestane in human urine by gas chromatography/mass spectrometry: development and validation of a method using MO-TMS derivatives. Rapid Communications in Mass Spectrometry, 2010, 24, 3297-3302.	0.7	10
75	Investigation on the application of DNA forensic human identification techniques to detect homologous blood transfusions in doping control. Talanta, 2013, 110, 28-31.	2.9	10
76	Application of DNA-based forensic analysis for the detection of homologous transfusion of whole blood and of red blood cell concentrates in doping control. Forensic Science International, 2016, 265, 204-210.	1.3	10
77	Fast IRMS screening of pseudoendogenous steroids in doping analyses. Drug Testing and Analysis, 2017, 9, 1804-1812.	1.6	10
78	Development and validation of a method to confirm the exogenous origin of prednisone and prednisolone by GCâ€Câ€IRMS. Drug Testing and Analysis, 2019, 11, 1615-1628.	1.6	10
79	Urinary excretion profile of methiopropamine in mice following intraperitoneal administration: A liquid chromatography–tandem mass spectrometry investigation. Drug Testing and Analysis, 2021, 13, 91-100.	1.6	10
80	Detection of Homologous Blood Transfusion in Sport Doping by Flow Cytofluorimetry: State of the Art and New Approaches to Reduce the Risk of False-Negative Results. Frontiers in Sports and Active Living, 2022, 4, 808449.	0.9	10
81	Urinary excretion profiles of toremifene metabolites by liquid chromatography-mass spectrometry. Towards targeted analysis to relevant metabolites in doping control. Analytical and Bioanalytical Chemistry, 2011, 401, 529-541.	1.9	9
82	Drugâ€drug interaction and doping, part 1: An <i>in vitro</i> study on the effect of nonâ€prohibited drugs on the phase I metabolic profile of toremifene. Drug Testing and Analysis, 2014, 6, 482-491.	1.6	9
83	Synthetic isoflavones and doping: A novel class of aromatase inhibitors?. Drug Testing and Analysis, 2019, 11, 208-214.	1.6	9
84	Detection of recombinant insulins in human urine by liquid chromatography–electrospray ionization tandem mass spectrometry after immunoaffinity purification based on monolithic microcolumns. Analytical and Bioanalytical Chemistry, 2019, 411, 8153-8162.	1.9	9
85	Microwave irradiation for a fast gas chromatography–mass spectrometric analysis of polysaccharide-based plasma volume expanders in human urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 3024-3032.	1.2	8
86	Human hepatoma cell lines on gas foaming templated alginate scaffolds for in vitro drug-drug interaction and metabolism studies. Toxicology in Vitro, 2015, 30, 331-340.	1.1	8
87	Multianalyte LC–MS-based methods in doping control: what are the implications for doping athletes?. Bioanalysis, 2016, 8, 1129-1132.	0.6	8
88	Detection of clostebol in sports: Accidental doping?. Drug Testing and Analysis, 2020, 12, 1561-1569.	1.6	8
89	Urinary Elimination of Ecdysterone and Its Metabolites Following a Single-Dose Administration in Humans. Metabolites, 2021, 11, 366.	1.3	8
90	Doping control container for urine stabilization: a pilot study. Drug Testing and Analysis, 2017, 9, 699-712.	1.6	7

#	Article	IF	CITATIONS
91	Influence of Indomethacin on Steroid Metabolism: Endocrine Disruption and Confounding Effects in Urinary Steroid Profiling of Anti-Doping Analyses. Metabolites, 2020, 10, 463.	1.3	7
92	Influence of Pain Killers on the Urinary Anabolic Steroid Profile. Journal of Analytical Toxicology, 2020, 44, 871-879.	1.7	7
93	Detection and quantitation of ecdysterone in human serum by liquid chromatography coupled to tandem mass spectrometry. Steroids, 2020, 157, 108603.	0.8	7
94	Metabolic profile of the synthetic drug 4,4′-dimethylaminorex in urine by LC–MS-based techniques: selection of the most suitable markers of its intake. Forensic Toxicology, 2021, 39, 89-100.	1.4	7
95	Coupling high-resolution mass spectrometry and chemometrics for the structural characterization of anabolic-androgenic steroids and the early detection of unknown designer structures. Talanta, 2021, 227, 122173.	2.9	7
96	Recent progress in the detection of the administration of natural hormones: Special focus on Testosterone. Toxin Reviews, 1999, 18, 125-144.	1.5	6
97	Drug–drug interaction and doping: Effect of nonâ€prohibited drugs on the urinary excretion profile of methandienone. Drug Testing and Analysis, 2018, 10, 1554-1565.	1.6	6
98	Detection of 5αâ€reductase inhibitors by UPLC–MS/MS: Application to the definition of the excretion profile of dutasteride in urine. Drug Testing and Analysis, 2019, 11, 1737-1746.	1.6	6
99	Validation of steroid sulfates deconjugation for metabolic studies. Application to human urine samples. Journal of Pharmacological and Toxicological Methods, 2020, 106, 106938.	0.3	6
100	Carbon isotopic characterization of prednisolone and prednisone pharmaceutical formulations: Implications in antidoping analysis. Drug Testing and Analysis, 2020, 12, 1587-1598.	1.6	6
101	Serum Levels of Brain-Derived Neurotrophic Factor and Other Neurotrophins in Elite Athletes: Potential Markers of the Use of Transcranial Direct Current Stimulation in Sport. Frontiers in Sports and Active Living, 2021, 3, 619573.	0.9	6
102	Effects of the administration of miconazole by different routes on the biomarkers of the "steroidal module―of the Athlete Biological Passport. Drug Testing and Analysis, 2021, 13, 1712-1726.	1.6	6
103	Controlled administration of dehydrochloromethyltestosterone in humans: Urinary excretion and long-term detection of metabolites for anti-doping purpose. Journal of Steroid Biochemistry and Molecular Biology, 2021, 214, 105978.	1.2	6
104	A rapid analytical method for the detection of plasma volume expanders and mannitol based on the urinary saccharides and polyalcohols profile. Drug Testing and Analysis, 2011, 3, 896-905.	1.6	5
105	A simple and rapid preâ€confirmation method to distinguish endogenous human haemoglobin from synthetic haemoglobinâ€based oxygen carriers in doping control. Electrophoresis, 2011, 32, 2915-2918.	1.3	5
106	Metabolism of boldione in humans by mass spectrometric techniques: detection of pseudoendogenous metabolites. Drug Testing and Analysis, 2013, 5, 834-842.	1.6	5
107	AÂmodified procedure based on a vacuum-driven blotting system for the detection of erythropoietin and its analogs. Bioanalysis, 2014, 6, 1605-1615.	0.6	5
108	Inâ€depth gas chromatography/tandem mass spectrometry fragmentation analysis of formestane and evaluation of mass spectral discrimination of isomeric 3â€ketoâ€4â€ene hydroxy steroids. Rapid Communications in Mass Spectrometry, 2020, 34, e8937.	0.7	5

#	Article	IF	CITATIONS
109	Detecting the abuse of 19â€norsteroids in doping controls: A new gas chromatography coupled to isotope ratio mass spectrometry method for the analysis of 19â€norandrosterone and 19â€noretiocholanolone. Drug Testing and Analysis, 2021, 13, 770-784.	1.6	5
110	Influence of synthetic isoflavones on selected urinary steroid biomarkers: Relevance to doping control. Steroids, 2021, 174, 108900.	0.8	5
111	In vitro metabolic profile of mexedrone, a mephedrone analog, studied by high―and lowâ€resolution mass spectrometry. Drug Testing and Analysis, 2022, 14, 269-276.	1.6	5
112	Metabolomics workflow as a driven tool for rapid detection of metabolites in doping analysis. Development and validation. Rapid Communications in Mass Spectrometry, 2022, 36, e9217.	0.7	5
113	Quantification of thyroid hormones and analogs by liquid chromatography coupled to mass spectrometry. Preliminary results in athletes and nonâ€athletes serum samples. Drug Testing and Analysis, 2022, 14, 1438-1450.	1.6	5
114	Comparing metabolic profiles between female endurance athletes and non-athletes reveals differences in androgen and corticosteroid levels. Journal of Steroid Biochemistry and Molecular Biology, 2022, 219, 106081.	1.2	5
115	Liposomes as potential masking agents in sport doping. Part 2: Detection of liposomeâ€entrapped haemoglobin by flow cytofluorimetry. Drug Testing and Analysis, 2017, 9, 208-215.	1.6	4
116	Liposomes as potential masking agents in sport doping. Part 1: analysis of phospholipids and sphingomyelins in drugs and biological fluids by aqueous normalâ€phase liquid chromatographyâ€tandem mass spectrometry. Drug Testing and Analysis, 2017, 9, 75-86.	1.6	4
117	An investigation on the metabolic pathways of synthetic isoflavones by gas chromatography coupled to high accuracy mass spectrometry. Rapid Communications in Mass Spectrometry, 2019, 33, 1485-1493.	0.7	4
118	Metabolism of formestane in humans: Identification of urinary biomarkers for antidoping analysis. Steroids, 2019, 146, 34-42.	0.8	4
119	5αâ€reductase inhibitors: Evaluation of their potential confounding effect on GCâ€Câ€IRMS doping analysis. Drug Testing and Analysis, 2021, 13, 1852-1861.	1.6	4
120	Mass spectrometric analysis of 7â€oxygenated androstâ€5â€ene structures. Influence in trimethylsilyl derivative formation. Rapid Communications in Mass Spectrometry, 2020, 34, e8834.	0.7	4
121	Thyroid metabolism and supplementation: A review framed in sports environment. Drug Testing and Analysis, 2022, 14, 1176-1186.	1.6	4
122	Evaluation of longitudinal <sup>13</sup> C IRMS data in antidoping analysis. Drug Testing and Analysis, 0, , .	1.6	4
123	Smoking habits of italian athletes undergoing antiâ€doping control. Drug Testing and Analysis, 2016, 8, 133-135.	1.6	3
124	Effect of nonâ€prohibited drugs on the phase II metabolic profile of morphine. An in vitro investigation for doping control purposes. Drug Testing and Analysis, 2018, 10, 984-994.	1.6	3
125	Detection of urinary arimistane metabolites in humans using liquid chromatography–mass spectrometry: Complementary results to gas chromatography mass spectrometric data and its application to antidoping analyses. Rapid Communications in Mass Spectrometry, 2021, 35, e9080.	0.7	3
126	Lowâ€energy electron ionization optimization for steroidomics analysis using highâ€resolution mass spectrometry. Rapid Communications in Mass Spectrometry, 2021, 35, e9196.	0.7	3

#	Article	IF	CITATIONS
127	Urinary excretion and effects on visual placing response in mice of gamma-valero-lactone, an alternative to gamma‑hydroxy-butyrate for drug-facilitated sexual assault. Emerging Trends in Drugs, Addictions, and Health, 2022, 2, 100028.	0.5	3
128	The effect of zolpidem on cognitive function and postural control at high altitude. Sleep, 2018, 41, .	0.6	2
129	Influence of Saw palmetto and Pygeum africana extracts on the urinary concentrations of endogenous anabolic steroids: Relevance to doping analysis. Phytomedicine Plus, 2021, 1, 100005.	0.9	2
130	Arimistane: Degradation product or metabolite of 7â€oxoâ€DHEA?. Drug Testing and Analysis, 2021, 13, 1430-1439.	1.6	2
131	Application of liquid chromatography coupled to data-independent acquisition mass spectrometry for the metabolic profiling of N-ethyl heptedrone. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1185, 122989.	1.2	2
132	Optimization of a method to detect levothyroxine and related compounds in serum and urine by liquid chromatography coupled to triple quadrupole mass spectrometry. Journal of Pharmacological and Toxicological Methods, 2022, 115, 107169.	0.3	2
133	Corticosteroid Biosynthesis Revisited: Substrate Specificity of Steroid 21â€Hydroxylase. FASEB Journal, 2020, 34, 1-1.	0.2	0